Araştırma Makalesi
Yıl 2022,
, 218 - 222, 30.06.2022
Öz
Kaynakça
- 1. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA: A Cancer Journal for Clinicians. 2019;69(5):363-385.
- 2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209-249.
- 3. Combes G, Alharbi I, Braga LG, Elowe S. Playing polo during mitosis: PLK1 takes the lead. Oncogene. 2017;36(34):4819-4827.
- 4. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000;21(3):485-495.
- 5. Chopra P, Sethi G, Dastidar SG, Ray A. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert opinion on investigational drugs. 2010;19(1):27-43.
- 6. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nature Reviews Cancer. 2006;6(4):321-330.
- 7. Shi J, Ren Y, Ma J, et al. Novel CD44-targeting and pH/redox-dual-stimuli-responsive core–shell nanoparticles loading triptolide combats breast cancer growth and lung metastasis. Journal of Nanobiotechnology. 2021;19(1):188.
- 8. Degenhardt Y, Lampkin T. Targeting Polo-like kinase in cancer therapy. Clinical cancer research. 2010;16(2):384-389.
- 9. Choi M, Kim W, Cheon MG, Lee C-W, Kim J-E. Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells. Cancer Letters. 2015;357(2):591-601.
- 10. Keppner S, Proschak E, Kaufmann M, Strebhardt K, Schneider G, Spänkuch B. Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle. 2010;9(4):761-774.
- 11. Lee KS, Burke TR, Park J-E, Bang JK, Lee E. Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy. Trends in Pharmacological Sciences. 2015;36(12):858-877.
- 12. Su S, Chhabra G, Singh CK, Ndiaye MA, Ahmad N. PLK1 inhibition-based combination therapies for cancer management. Translational Oncology. 2022;16:101332.
- 13. Bayat Mokhtari R, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022-38043.
- 14. Gutteridge RE, Ndiaye MA, Liu X, Ahmad N. Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics. Molecular cancer therapeutics. 2016;15(7):1427-1435.
- 15. Ergul M, Bakar-Ates F. RO3280: a novel PLK1 inhibitor, suppressed the proliferation of MCF-7 breast cancer cells through the induction of cell cycle arrest at G2/M point. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2019;19(15):1846-1854.
- 16. ERGÜL M. Investigation of potential DNA damaging and apoptotic effects of PLK1 inhibitor SBE13 in breast cancer cell line MDA-MB-231. Cumhuriyet Science Journal. 2020;41(4):802-807.
- 17. Hikichi Y, Honda K, Hikami K, et al. TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens. Molecular cancer therapeutics. 2012;11(3):700-709.
- 18. Lange L, Keppner-Witter S, Grigat J, Spänkuch B. Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 status. Oncotarget. 2014;5(8):2263-2275.
Investigation of the potential antitumor activity of PLK1 inhibitor SBE13 in colon cancer cell line HT29
Öz
Background: High levels of Polo-like kinase 1 (PLK1), which are abnormally expressed in many tumor types, are known to contribute to tumorigenesis and poor prognosis. Therefore, specific targeting of PLK1 is an important strategy for cancer therapy. This study, it was aimed to investigate the cytotoxic effect of SBE13, one of the PLK1 inhibitors, against HT29 colon adenocarcinoma cells and its apoptotic potential.
Methods: The cytotoxic effect of SBE13 on HT29 was determined by XTT colorimetric assay. Flow cytometry was also used to determine apoptosis.
Results: SBE13 showed a dose-dependent cytotoxic effect in HT29 cells and its IC50 value was calculated as 11.79 µM for 48 h. Moreover, the Annexin V binding assay revealed that SBE13 treatment significantly increased apoptosis in HT29 cells.
Conclusion: Generally, SBE13 exerts a cytotoxic effect promoted by apoptosis in colon cancer cells HT29. Although the anticancer efficacy of SBE13 in colon cancer is promising, this potential effect should be reinforced by further studies.
Anahtar Kelimeler
Kaynakça
- 1. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA: A Cancer Journal for Clinicians. 2019;69(5):363-385.
- 2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209-249.
- 3. Combes G, Alharbi I, Braga LG, Elowe S. Playing polo during mitosis: PLK1 takes the lead. Oncogene. 2017;36(34):4819-4827.
- 4. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000;21(3):485-495.
- 5. Chopra P, Sethi G, Dastidar SG, Ray A. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert opinion on investigational drugs. 2010;19(1):27-43.
- 6. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nature Reviews Cancer. 2006;6(4):321-330.
- 7. Shi J, Ren Y, Ma J, et al. Novel CD44-targeting and pH/redox-dual-stimuli-responsive core–shell nanoparticles loading triptolide combats breast cancer growth and lung metastasis. Journal of Nanobiotechnology. 2021;19(1):188.
- 8. Degenhardt Y, Lampkin T. Targeting Polo-like kinase in cancer therapy. Clinical cancer research. 2010;16(2):384-389.
- 9. Choi M, Kim W, Cheon MG, Lee C-W, Kim J-E. Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells. Cancer Letters. 2015;357(2):591-601.
- 10. Keppner S, Proschak E, Kaufmann M, Strebhardt K, Schneider G, Spänkuch B. Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle. 2010;9(4):761-774.
- 11. Lee KS, Burke TR, Park J-E, Bang JK, Lee E. Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy. Trends in Pharmacological Sciences. 2015;36(12):858-877.
- 12. Su S, Chhabra G, Singh CK, Ndiaye MA, Ahmad N. PLK1 inhibition-based combination therapies for cancer management. Translational Oncology. 2022;16:101332.
- 13. Bayat Mokhtari R, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022-38043.
- 14. Gutteridge RE, Ndiaye MA, Liu X, Ahmad N. Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics. Molecular cancer therapeutics. 2016;15(7):1427-1435.
- 15. Ergul M, Bakar-Ates F. RO3280: a novel PLK1 inhibitor, suppressed the proliferation of MCF-7 breast cancer cells through the induction of cell cycle arrest at G2/M point. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2019;19(15):1846-1854.
- 16. ERGÜL M. Investigation of potential DNA damaging and apoptotic effects of PLK1 inhibitor SBE13 in breast cancer cell line MDA-MB-231. Cumhuriyet Science Journal. 2020;41(4):802-807.
- 17. Hikichi Y, Honda K, Hikami K, et al. TAK-960, a Novel, Orally Available, Selective Inhibitor of Polo-Like Kinase 1, Shows Broad-spectrum Preclinical Antitumor Activity in Multiple Dosing Regimens. Molecular cancer therapeutics. 2012;11(3):700-709.
- 18. Lange L, Keppner-Witter S, Grigat J, Spänkuch B. Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 status. Oncotarget. 2014;5(8):2263-2275.
Toplam 18 adet kaynakça vardır.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Konular | Sağlık Kurumları Yönetimi |
| Bölüm | Cerrahi Tıp Bilimleri Araştırma Yazıları |
| Yazarlar | |
| Yayımlanma Tarihi | 30 Haziran 2022 |
| Kabul Tarihi | 27 Haziran 2022 |
| Yayımlandığı Sayı | Yıl 2022 |